Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Shattuck Labs Inc's Business Segments
Shattuck Labs Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Reportable0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Reportable0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | - | - |
Description of Shattuck Labs Inc
Shattuck Labs Inc is a biotechnology company that is focused on developing next-generation therapies for cancer treatment. The company was founded in 2016 and is headquartered in Austin, Texas. Shattuck Labs has a broad range of expertise in cancer biology, immunotherapy and drug development.
The company's lead product candidate is called SL-172154, which is an immunotherapy that targets the CD47 trimerization domain. This drug facilitates the phagocytosis of cancer cells by immune cells, which helps to promote an anti-tumor immune response. SL-172154 is currently in Phase 1 clinical trials for patients with solid tumors.
Shattuck Labs has also developed a proprietary platform called Agonist Redirected Checkpoint (ARC) that allows for the generation of novel immunotherapies. The ARC platform combines an agonist ligand that activates immune cells with a checkpoint inhibitor that helps to prevent immunosuppression. This technology can also enable targeted drug delivery to cancer cells, reducing the potential for off-target effects.
In addition to their pipeline of drug candidates, Shattuck Labs has established strategic partnerships with companies such as Takeda Pharmaceuticals and Astellas Pharma. Through these partnerships, the company is able to access additional resources and expertise to further develop their immuno-oncology therapies.
Overall, Shattuck Labs Inc is a dynamic company that is positioned for success in the emerging field of cancer immunotherapy. Their innovative platform technology and promising lead product candidate make them a company to watch in the biotech industry.
The company's lead product candidate is called SL-172154, which is an immunotherapy that targets the CD47 trimerization domain. This drug facilitates the phagocytosis of cancer cells by immune cells, which helps to promote an anti-tumor immune response. SL-172154 is currently in Phase 1 clinical trials for patients with solid tumors.
Shattuck Labs has also developed a proprietary platform called Agonist Redirected Checkpoint (ARC) that allows for the generation of novel immunotherapies. The ARC platform combines an agonist ligand that activates immune cells with a checkpoint inhibitor that helps to prevent immunosuppression. This technology can also enable targeted drug delivery to cancer cells, reducing the potential for off-target effects.
In addition to their pipeline of drug candidates, Shattuck Labs has established strategic partnerships with companies such as Takeda Pharmaceuticals and Astellas Pharma. Through these partnerships, the company is able to access additional resources and expertise to further develop their immuno-oncology therapies.
Overall, Shattuck Labs Inc is a dynamic company that is positioned for success in the emerging field of cancer immunotherapy. Their innovative platform technology and promising lead product candidate make them a company to watch in the biotech industry.
Shattuck Labs Inc. is a clinical-stage biotechnology company that is focused on innovating and commercializing advanced therapeutics aimed at treating cancer and autoimmune diseases. By leveraging a proprietary approach, the company has created segments and platforms that are tailored to meet the unique needs of patients facing these challenging health conditions.
Segments:
Shattuck Labs has organized its business into two primary segments:
1. Oncology: This segment is devoted to revolutionary cancer therapies and is further subdivided based on the modalities employed.
- Fusion Protein Platform: Utilizing Shattucks proprietary fusion protein technology, this platform is engineered to specifically modify cytokine (interleukin-2) to selectively activate immune cells against cancer while minimizing systemic toxicity. The ability to achieve localized dosing enhances therapeutic effects within the tumor microenvironment, altering the landscape of treatment by focusing on precise targeting of activated immune cells.
- Agonist Redirected Checkpoint (ARC) Platform: This innovative platform enables the development of a novel class of tumor-targeted immunotherapies. ARCs effectively redirect immune cells to interact with checkpoint molecules expressed on cancer cells. The goal is to harness and exploit the regulatory functions of the checkpoint pathways, helping to neutralize cancers ability to evade immune responses.
- Bispecific Fusion Protein Technology: This segment focuses on creating bispecific fusion proteins that can engage multiple types of immune cells. By activating these cells simultaneously, the technology aims to enhance the overall anti-tumor immune response, making it a promising approach for more potent cancer therapies.
2. Autoimmune Diseases: This segment is specifically designed to produce therapeutics targeting autoimmune conditions. Products aimed at modulating immune responses to reduce the burden of these diseases include:
- PD-1xCTLA-4 Bispecific Antagonist: This product is tailored to leverage the immune system to combat autoimmune diseases actively. By targeting dual pathways, the compound is designed to achieve a more effective immunological response against these conditions.
Products:
Shattuck Labs Inc. has developed an array of products with the intent of providing relief to patients afflicted by cancer and autoimmune diseases. Key products include:
1. SL-172154: A cytokine-fusion protein that selectively aims at activated immune cells within the tumor microenvironment. It is important to note that this drug is currently undergoing Phase I clinical trials, exploring its safety and efficacy in cancer treatments.
2. SL-279252: This is an agonist-redirected checkpoint (ARC) currently in preclinical development. This compound is designed to produce a range of new checkpoint inhibitors, enhancing their effectiveness against various tumor types.
3. SL-15252: Another product in the pipeline, this bispecific fusion protein is being developed to potentiate the immune response in cancer patients. Like SL-279252, it is currently in preclinical stages of development.
Services:
Shattuck Labs extends a variety of services designed to enhance the overall care and experience of patients dealing with cancer and autoimmune diseases. These services encompass:
1. Clinical Trials: The company maintains an extensive clinical trial program focused on advancing treatments across a spectrum of cancer types and autoimmune disorders. This program seeks to gather crucial data on the safety and effectiveness of its novel therapies.
2. Healthcare Providers Services: Shattuck Labs provides healthcare professionals with a suite of services, including educational resources and treatment plans that equip clinicians with the necessary knowledge and tools to treat their patients effectively. The access to clinical experts further ensures high-quality patient care.
3. Patient Care Services: The company is committed to patient-focused care by offering support programs aimed at enhancing the quality of life for patients. These initiatives may include informational resources, mental health support, and other assistance that fosters better patient outcomes.
Conclusion
In summary, Shattuck Labs Inc. is at the forefront of developing cutting-edge therapies tailored for cancer and autoimmune diseases. Through its well-defined segments, proprietary platforms, and multi-faceted product and service offerings, the company is dedicated to innovating solutions that harness the power of the immune system to improve patient health and quality of life. The commitment to research and patient management positions Shattuck Labs as a significant player in the evolving landscape of biotechnology.
Segments:
Shattuck Labs has organized its business into two primary segments:
1. Oncology: This segment is devoted to revolutionary cancer therapies and is further subdivided based on the modalities employed.
- Fusion Protein Platform: Utilizing Shattucks proprietary fusion protein technology, this platform is engineered to specifically modify cytokine (interleukin-2) to selectively activate immune cells against cancer while minimizing systemic toxicity. The ability to achieve localized dosing enhances therapeutic effects within the tumor microenvironment, altering the landscape of treatment by focusing on precise targeting of activated immune cells.
- Agonist Redirected Checkpoint (ARC) Platform: This innovative platform enables the development of a novel class of tumor-targeted immunotherapies. ARCs effectively redirect immune cells to interact with checkpoint molecules expressed on cancer cells. The goal is to harness and exploit the regulatory functions of the checkpoint pathways, helping to neutralize cancers ability to evade immune responses.
- Bispecific Fusion Protein Technology: This segment focuses on creating bispecific fusion proteins that can engage multiple types of immune cells. By activating these cells simultaneously, the technology aims to enhance the overall anti-tumor immune response, making it a promising approach for more potent cancer therapies.
2. Autoimmune Diseases: This segment is specifically designed to produce therapeutics targeting autoimmune conditions. Products aimed at modulating immune responses to reduce the burden of these diseases include:
- PD-1xCTLA-4 Bispecific Antagonist: This product is tailored to leverage the immune system to combat autoimmune diseases actively. By targeting dual pathways, the compound is designed to achieve a more effective immunological response against these conditions.
Products:
Shattuck Labs Inc. has developed an array of products with the intent of providing relief to patients afflicted by cancer and autoimmune diseases. Key products include:
1. SL-172154: A cytokine-fusion protein that selectively aims at activated immune cells within the tumor microenvironment. It is important to note that this drug is currently undergoing Phase I clinical trials, exploring its safety and efficacy in cancer treatments.
2. SL-279252: This is an agonist-redirected checkpoint (ARC) currently in preclinical development. This compound is designed to produce a range of new checkpoint inhibitors, enhancing their effectiveness against various tumor types.
3. SL-15252: Another product in the pipeline, this bispecific fusion protein is being developed to potentiate the immune response in cancer patients. Like SL-279252, it is currently in preclinical stages of development.
Services:
Shattuck Labs extends a variety of services designed to enhance the overall care and experience of patients dealing with cancer and autoimmune diseases. These services encompass:
1. Clinical Trials: The company maintains an extensive clinical trial program focused on advancing treatments across a spectrum of cancer types and autoimmune disorders. This program seeks to gather crucial data on the safety and effectiveness of its novel therapies.
2. Healthcare Providers Services: Shattuck Labs provides healthcare professionals with a suite of services, including educational resources and treatment plans that equip clinicians with the necessary knowledge and tools to treat their patients effectively. The access to clinical experts further ensures high-quality patient care.
3. Patient Care Services: The company is committed to patient-focused care by offering support programs aimed at enhancing the quality of life for patients. These initiatives may include informational resources, mental health support, and other assistance that fosters better patient outcomes.
Conclusion
In summary, Shattuck Labs Inc. is at the forefront of developing cutting-edge therapies tailored for cancer and autoimmune diseases. Through its well-defined segments, proprietary platforms, and multi-faceted product and service offerings, the company is dedicated to innovating solutions that harness the power of the immune system to improve patient health and quality of life. The commitment to research and patient management positions Shattuck Labs as a significant player in the evolving landscape of biotechnology.